SNBL to Acquire Satsuma Pharmaceuticals, Shares Surge

Satsuma Pharmaceuticals (NASDAQ: STSA) shares have more than doubled premarket after it was announced Sunday evening that Shin Nippon Biomedical Laboratories (SNBL) will acquire the company.

SNBL will pay $0.91 per share in cash at the transaction’s close, plus one non-tradeable contingent value right (CVR) of up to $5.77 per share.

WELCOME BONUS - Free Share Bundle When You Invest £50! Open a UK Investment Account: Shares, ISAs, Managed Portfolio Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply. IG

5.0

View Offers

Empfohlener Broker Multi Asset Platform

Social-Trading-Pionier mit Aktien, ETFs, Krypto und CFDs, Copy Trading inklusive. eToro

5.0

Weitere Informationen 52% of retail investor accounts lose money when trading CFDs with this provider. eToro is a multi asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Satsuma shares are currently trading 156% above Friday’s close in premarket trading at the $1.68 level.

The CVR is payable according to the future license, sale, or any other monetization events related to STS101, an investigational therapeutic product candidate for the acute treatment of migraines.

Satsuma submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in March for STS101.

“We believe that STS101 will contribute to improving the quality of life of patients suffering from migraine,” commented Dr. Ryoichi Nagata, Chairman and President of SNBL.

Meanwhile, President and Chief Executive Officer of Satsuma, John Kollins, stated: “After carefully and comprehensively considering strategic options for Satsuma and STS101, the Satsuma Board of Directors believes that the acquisition of Satsuma by SNBL is the best strategic alternative for Satsuma and that this transaction will maximize value for our stockholders.”